Dragonfly was founded by a management team with extensive pharmaceutical and biotechnology industry experience in the discovery and development of antibody therapeutics. The company’s pipeline of products will address blockbuster products in inflammation, autoimmunity and cancer. Headquartered in the United States, Dragonfly operates its research and development laboratories in Shanghai, China, and has a global strategy to market its products in the US, Europe and select rest-of-world markets.